151 related articles for article (PubMed ID: 25222595)
21. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
[TBL] [Abstract][Full Text] [Related]
22. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
[TBL] [Abstract][Full Text] [Related]
23. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
[TBL] [Abstract][Full Text] [Related]
24. Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel-Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3.
Bushart DD; Zalon AJ; Zhang H; Morrison LM; Guan Y; Paulson HL; Shakkottai VG; McLoughlin HS
Cerebellum; 2021 Feb; 20(1):41-53. PubMed ID: 32789747
[TBL] [Abstract][Full Text] [Related]
25. Homozygosity enhances severity in spinocerebellar ataxia type 3.
Carvalho DR; La Rocque-Ferreira A; Rizzo IM; Imamura EU; Speck-Martins CE
Pediatr Neurol; 2008 Apr; 38(4):296-9. PubMed ID: 18358414
[TBL] [Abstract][Full Text] [Related]
26. Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy.
Matos CA; de Almeida LP; Nóbrega C
J Neurochem; 2019 Jan; 148(1):8-28. PubMed ID: 29959858
[TBL] [Abstract][Full Text] [Related]
27. Generation of induced pluripotent stem cells from a patient with spinocerebellar ataxia type 3.
Soong BW; Syu SH; Wen CH; Ko HW; Wu ML; Hsieh PC; Hwang SM; Lu HE
Stem Cell Res; 2017 Jan; 18():29-32. PubMed ID: 28395798
[TBL] [Abstract][Full Text] [Related]
28. Generation of human embryonic stem cell line chHES-472 from abnormal embryos diagnosed with Spinocerebellar ataxia type 3.
Liu L; Zeng S; Sun Y; Zhou X; Chen J; Du J; Lu G; Lin G; Ouyang Q
Stem Cell Res; 2016 Nov; 17(3):584-586. PubMed ID: 27934588
[TBL] [Abstract][Full Text] [Related]
29. Transcription factor EB-mediated mesenchymal stem cell therapy induces autophagy and alleviates spinocerebellar ataxia type 3 defects in neuronal cells model.
Han X; de Dieu Habimana J; Li AL; Huang R; Mukama O; Deng W; Wang L; Zhang Y; Wang W; Deng S; Peng K; Ni B; Zhang S; Huang J; Yan XX; Li Z
Cell Death Dis; 2022 Jul; 13(7):622. PubMed ID: 35851059
[TBL] [Abstract][Full Text] [Related]
30. Generation of induced pluripotent stem cell line (ZZUi0014-A) from a patient with spinocerebellar ataxia type 3.
Wang Y; Sun H; Wang Z; Yue Y; Zhang R; Yang J; Liu Y; Liu H; Zhang Q; Zhang S; Zhang J; Xu Y; Shi C
Stem Cell Res; 2019 Dec; 41():101564. PubMed ID: 31639609
[TBL] [Abstract][Full Text] [Related]
31. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
32. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice.
Mendonça LS; Nóbrega C; Hirai H; Kaspar BK; Pereira de Almeida L
Brain; 2015 Feb; 138(Pt 2):320-35. PubMed ID: 25527827
[TBL] [Abstract][Full Text] [Related]
33. The Role of MicroRNAs in Spinocerebellar Ataxia Type 3.
Krauss S; Evert BO
J Mol Biol; 2019 Apr; 431(9):1729-1742. PubMed ID: 30664869
[TBL] [Abstract][Full Text] [Related]
34. Transcriptional profiling and biomarker identification reveal tissue specific effects of expanded ataxin-3 in a spinocerebellar ataxia type 3 mouse model.
Toonen LJA; Overzier M; Evers MM; Leon LG; van der Zeeuw SAJ; Mei H; Kielbasa SM; Goeman JJ; Hettne KM; Magnusson OT; Poirel M; Seyer A; 't Hoen PAC; van Roon-Mom WMC
Mol Neurodegener; 2018 Jun; 13(1):31. PubMed ID: 29929540
[TBL] [Abstract][Full Text] [Related]
35. Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3.
Toonen LJ; Schmidt I; Luijsterburg MS; van Attikum H; van Roon-Mom WM
Sci Rep; 2016 Oct; 6():35200. PubMed ID: 27731380
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of NF-κB in astrocytes is sufficient to delay neurodegeneration induced by proteotoxicity in neurons.
Li YX; Sibon OCM; Dijkers PF
J Neuroinflammation; 2018 Sep; 15(1):261. PubMed ID: 30205834
[TBL] [Abstract][Full Text] [Related]
37. Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3.
Griffin JL; Cemal CK; Pook MA
Physiol Genomics; 2004 Feb; 16(3):334-40. PubMed ID: 14679302
[TBL] [Abstract][Full Text] [Related]
38. Recent therapeutic prospects for Machado-Joseph disease.
Costa MDC
Curr Opin Neurol; 2020 Aug; 33(4):519-526. PubMed ID: 32657894
[TBL] [Abstract][Full Text] [Related]
39. Machado-Joseph disease and other rare spinocerebellar ataxias.
Matilla-Dueñas A
Adv Exp Med Biol; 2012; 724():172-88. PubMed ID: 22411243
[TBL] [Abstract][Full Text] [Related]
40. Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3.
Suga N; Katsuno M; Koike H; Banno H; Suzuki K; Hashizume A; Mano T; Iijima M; Kawagashira Y; Hirayama M; Nakamura T; Watanabe H; Tanaka F; Sobue G
Neuropathol Appl Neurobiol; 2014 Aug; 40(5):628-39. PubMed ID: 23617879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
